Home
overview

Register by the 29th November to get £200 off your ticket! 

This conference brings you the latest advances in the RNA and genetic medicine space.

The SAE Media Group’s 15th Annual Conference RNA Therapeutics will be taking place on the 6-8 February 2024 in London.

This year's agenda has been validated by our advisory board:

  • Shalini Andersson, VP Oligonucleotide, AstraZeneca
  • Michelle Lynn Hall, Associate Vice President, Genetic Medicine, Eli Lilly
  • Edward Hennessy,Senior Director, Discovery Chemistry, Moderna
  • Heinrich Hass,Senior Scientist,Johannes Gutenberg University Mainz Formerly Vice President RNA Formulation & Drug Delivery, BioNTech

Why attend?

RNA therapeutics is a rapidly expanding industry with increasingly growing potential for immunotherapy, personalised medicines, and treatment of genetic, infectious and chronic diseases. Don't miss this opportunity to network with the big pharma and biotech community of global experts leading the way in RNA drug discovery and development.

This is the only event that will:

Showcase new representation and insights from big pharma companies, with a high-level agenda focussing on driving industry advancement, whilst also offering benchmarking and networking opportunities for leading figures in the industry.

What's different this year?

  • Pre-conference focus day - 'Advances in RNA delivery technologies for enhanced target specificity'
  • Two-day main conference with morning keynote plenaries and parallel afternoon topic streams: 

               - 'Preclinical Development Target ID and Validation'
               - 'Analytical Development' 
               - 'Translational Research'
               - 'CMC and Manufacturing'

 

  • Gain insight into the key drivers and challenges of this fast-expanding industry such as target specificity for extra-hepatic delivery.
  • Engage in the growing advances and development of novel RNA molecules in the treatment of chronic respiratory, neurodegenerative, and infectious diseases
  • Exclusive networking opportunities including dedicated networking breaks to connect with industry experts from Moderna, GSK, AstraZeneca, Bayer, AbbVie, Roche, Envisagenics, BioNTech, Alnylam, Dyne, Evox Therapeutics and many others.
  • Present your services, solutions and share your insight with a targeted audience of potential clients and partners through extensive marketing and promotional campaign which puts your brand in front of the major companies in the region.

 

Those who are at the centre of the genetic medicine industry should be attending this conference! 

Pharma and Biotech Directors, Managers and Heads of Departments of:

  • RNA
  • Genetic Medicine
  • Oligonucleotide Discovery
  • RNA Discovery
  • New Modalities
  • RNA Biology
  • RNA Formulation and Delivery
  • Targeted Delivery
  • Clinical Development
  • Pre-Clinical Development
  • Oligonucleotide Chemistry
  • Drug Discovery
  • Target Discovery
  • Medicinal Chemistry
  • RNA Development
  • RNA Vaccines
  • RNA Biochemistry
     

 


 

Conference agenda

clock

8:00

Registration & Coffee

The inaugural Advances in RNA Delivery Technologies for Enhanced Target Specificity Focus Day  will showcase cutting-edge innovations in RNA delivery vehicle design and development. Industry experts will explore new technologies and approaches to ensure safe, efficient and targeted delivery of RNA therapies. The sessions will explore the opportunities of lipid nano-particles, adeno-associated viruses and exosomes across nucelic acid therapeutic modalites and given the growing demand for extra-hepatic delivery, case studies will delve into the latest breakthroughs for delivery across the blood-brain barrier, directly to immune cells and to areas previously thought to be untargetable

clock

8:50

Chairman's Opening Remarks

clock

9:00

Optimising RNA therapeutic delivery with non-viral vectors

Florian Mann

Florian Mann, Lab Head Drug Targeting & Vectors, Bayer AG Pharmaceuticals

  • Understanding the clinical appeal of lipid nanoparticle delivery systems and other competing modes of delivery
  • Insight into how structure of LNPs effects function and efficacy
  • Overcoming the challenges holding back extra-hepatic delivery
  • Improving monitoring of RNA delivery with post-delivery imaging
  • clock

    9:30

    Discovery of novel amino lipids for mRNA delivery

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna

  •  An introduction to lipid nanoparticles (LNPs) for the delivery  of nucleic acids, with a focus on the role of the amino lipid  component
  • Medicinal chemistry strategies for optimizing lipid/LNP physical properties, pharmacokinetics, and biological performance
  •  Utilization of computational modelling to guide the design of improved delivery vehicles for mRNA
  • clock

    10:00

    Session resereved for lead sponsor

    clock

    10:30

    Morning Coffee

    clock

    11:00

    Improving the delivery of siRNA’s using GALNAc conjugates

    Muthiah Manohoran, Senior VP, Alnylam Pharmaceuticals

  •  Modifying siRNA chemistry to better complex with conjugatedelivery system
  • Gearing conjugation chemistry for targeted siRNA delivery to elicit desired therapeutic effect
  • Improving potency, specificity and safety of siRNAs foreffective delivery to target site
  • clock

    11:30

    Session resereved for sponsor

    clock

    12:00

    Applying viral vectors to deliver genetic material and AbbVie’s degradomers

    Hunter Adams

    Hunter Adams, Principal Scientist, AbbVie

     

  • AAVs are multi-component systems that can be tuned to modulate the system’s bioperformance 
  • Effective RNA/AAV vaccines must balance antigen expression, immunogenicity and tolerability 
  • AAV formulation design studies that highlight key considerations when developing an effective RNA/AAV
  • clock

    12:30

    Networking Lunch

    clock

    13:30

    Integrating Innovative Technologies into Oligo Therapeutics Discovery and Delivery

    Stephen Keane

    Stephen Keane, Scientist, ProQR

  •  Optimising the formulation of the new and rna editing therpaies and overcoming the new challenges this presents regarding dosage
  • Translating the work from animal studies to the clinic and how this compares with previous therapeutics
  • Predicting how these present great promise for future development of oligo therapeutics and RNA editied therapies
  • clock

    14:00

    Session reeserved for sponsor

    clock

    14:30

    Characterization and control strategies of mRNA LNP products in early clinical phase

    Eivor Ornskov, Principal Scientist, AstraZeneca

  • Quality attributes for mRNA LNP products will be outlined 
  • Impurities/degradation pathways of mRNA LNP products to consider
  • A snapshot of some key analytical methods
     
  • clock

    15:00

    Afternoon Tea

    clock

    15:30

    Session resereved for sponsor

    clock

    16:00

    Exploring Extracellular Vesicles as delivery agents for RNA

    Virginia Castilla-Llorente

    Virginia Castilla-Llorente, Associate Director, Evox Therapeutics Ltd

  • An introduction into the therapeutic potentials of Extracellular Vesicles
  • Advancing the RNA therapeutic landscape through the Evox platform for mRNA, siRNA, and gene editing EV delivery
  • Future perspectives: next steps in the development of EVs forthe delivery of RNA modalities
  • clock

    16:30

    Tailoring delivery systems for next generation mRNA therapeutics

    Heinrich Haas

    Heinrich Haas, Senior Scientist, Johannes Gutenberg University Mainz

  • Nanoparticle technologies for nucleotide and drug delivery systems
  • Structural and functional coherencies within selected delivery systems
  • Novel approaches and tailored solutions for future mRNA therapeutics
  • clock

    17:00

    Chairman’s Closing Remarks and Close of Day One

    clock

    7:00

    Registration & Coffee

    clock

    7:50

    Chairman's Opening Remarks

    clock

    8:00

    An in-depth review of current delivery and innovation in genetic medicine for the central nervous system

    Michelle Lynn-Hall, Advisor,

  • Exploring key challenges at the forefront of the next generation of genetic medicines
  • Utilising Nucleic acid innovation as a crucial component in the development of RNA therapeutics
  • Enhancing the RNA therapeutic field through strategic approaches to RNA therapeutic development
  • clock

    8:30

    Developing Oligonucleotides into Therapies: Opportunities and Challenges

    Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca

  •  Introduction to oligonucleotide therapeutics and the current landscape
  • Therapeutic promise of oligonucleotide modalities
  • Outlining some of the key challenges in oligonucleotide therapeutics including extra-hepatic delivery
  • clock

    9:00

    Session resereved for lead sponsor

    clock

    9:30

    Overcoming challenges with patient safety and pharmacovigilance with real-world evidence

    Michael von Forstner, Global Head of Patient Safety and Pharmacovigilance, Biogen International GmbH

  • Discuss the increasing role of real-world evidence in drugdevelopment and regulatory submissions
  •  Opportunities to use RWE to support post-marketing regulatorycommitments for drugs approved through the acceleratedapproval pathway
  • Considerations when designing a post-approval study usingreal-world evidence
  • clock

    10:00

    Morning Coffee

    clock

    10:30

    Session resereved for lead sponsor

    clock

    11:00

    Implementing an artificial micro-RNA treatment for Huntington’s

    Lucie Anderson

    Lucie Anderson, Research Scientist, Roche

  • Case study data from uniQure’s AMT-130 trial for a AAV delivered gene therapy
  • Considerations for the mechanism of action and distribution of AAV-miHTT
  • Optimising the administration of AAV-gene therapies for intrabrain delivery
  • clock

    11:30

    Advisory Board Fireside Chat: Advancing RNA therapeutics by improving drug-like properties

  • Upcoming RNA-based medicines beyond vaccines: What will be the next products? What should industry be looking to work on?
  • Delivery systems beyond LNPs: Will LNPs do the job or do we need more for targeted delivery, such as: extrahepatic and organ-specific delivery,BBB and tumours?
  • Types of RNA: What are the emerging ‘flavors’ and what is promising -saRNA, modRNA, circularRNA?
  • Shalini Andersson, Vice President Oligonucleotide Discovery, AstraZeneca

    Michelle Lynn-Hall, Advisor,

    Tamar Grossman, Vice President, Global Head of RNA and Targeted Therapeutics, Janssen Pharmaceutical Companies of Johnson & Johnson

    Heinrich Haas

    Heinrich Haas, Senior Scientist, Johannes Gutenberg University Mainz

    Edward Hennessy, Senior Director, Discovery Chemistry, Moderna

    clock

    12:00

    GalAhead™ platform: A Proprietary GalNAc-RNAi Therapeutic

    Jimmy Weterings

    Jimmy Weterings, Vice President Research, RNA Therapeutics & Delivery, Sirnaomics, Inc

  • Introduction to GalAhead, Sirnaomics’ GalNAc-RNAi therapeutic platform
  • Validation of technology in vivo and in vitro
  • Progress report on GalAhead-based programs

     

     

  • clock

    12:30

    Session resereved for lead sponsor

    clock

    13:00

    Networking Lunch

    clock

    14:00

    Chair's Opening Remarks

    clock

    14:10

    Understanding Which Potency Challenges Arise with mRNA Vaccines & How to Overcome them to Ensure a Safe & Efficient mRNA Vaccine

    Kaushik Thanki

    Kaushik Thanki, Director Early-Stage Formulation Process Development, BioNTech SE

  • Discussing the existing challenges with potency measurements for mRNA vaccines
  • Exploring the approaches used for analysing potency in mRNA vaccines
  • clock

    14:40

    Session resereved for sponsor

    clock

    15:10

    Understanding the Validation Lifecycle & Qualification Requirements to Guarantee a Rapid & Smooth Approval

    Thomas Goodnow

    Thomas Goodnow, Senior Scientist, GSK

  • How to facilitate the demands from regulatory agencies to provide a comprehensive understanding of the products and processes under validation
  • How to give evidence of a state of control and maintain regulatory compliance
  • How to adapt to the continuous processes development which are changing to meet requirements
  • clock

    15:40

    Afternoon Tea

    clock

    16:40

    Session resereved for sponsor

    clock

    17:10

    Harnessing Gene Activation to Target Cancer: Utilising Small Activating RNAs

    Nagy Habib

    Nagy Habib, Co-Founder and CMO , MiNA Therapeutics

  • Exploring Next-generation PTX_LNP™ formulations for delivering PTXmRNA™ to various tissues and cell types
  • Reviewing PTXcLNP™ enabling target protein expression in the vascular endothelium of the lung via the intravenous delivery
  • Case study: mRNA therapy to prevent lung oedema in Acute Respiratory Distress Syndrome
  • clock

    17:40

    Overcoming potency challenges of mRNA vaccines to maintain safe and efficacious vaccines

    Chris Burns, Head of Biotherapeutics and Advanced Therapies, MHRA

  • Overview of key challenges during the clinical development phase
  • Exploring molecular mechanisms of cytotoxicity to better design future ASO therapeutics
  • Regulatory strategies for use of platform data and prior knowledge
  • clock

    14:00

    Chair's Opening Remarks

    clock

    14:10

    AI/ML developed RNA therapeutics for neurodegenerative diseases

    Martin Akerman, Co-Founder & CTO, Envisagenics

  • Overcoming in-silico modelling challenges for neurodegenerative diseases
  • How Envisagenics’ SpliceCore platform can be used in designing antisense oligonucleotides
  • Translational R&D from in-silico to in-vitro for potential ASO candidates in neurodegenerative diseases
     
  • clock

    14:40

    Session Resereved for Sponsor

    clock

    15:10

    Reviewing RNA therapeutics as the next generation of genetic medicines

    Tae-Won Kim

    Tae-Won Kim, Vice President, Preclinical Development, Ionis Pharmaceuticals

  • Discussing current drug like properties of RNA modalities
  • Advancing RNA medicines beyond current vaccines products
  • Dissecting the challenges associated with targeted delivery of RNA based therapies
  • Understanding the future direction of RNA based drugs, with a focus on emerging, novel RNA modalities

     

  • clock

    15:40

    Afternoon Tea

    clock

    16:10

    An antisense oligonucleotide-based approach for the treatment of autosomal dominant optic atrophy

    Aditya Venkatesh

    Aditya Venkatesh, Senior Principal Scientist, Stoke Therapeutics Inc

  •  Introduction to Stoke’s proprietary research platform TANGO
  • Application of TANGO for the treatment of autosomal dominant optic atrophy (ADOA)
  • Pre-clinical pharmacology data for STK-002, Stoke’s clinical candidate for ADOA

     

  • clock

    16:40

    Session reserved for sponsor

    clock

    17:10

    Discovery to Clinic: mRNA as a Potential Treatment for Rare Disease

    Frank Jaschinski

    Frank Jaschinski, CSO, Secarna Pharmaceuticalsá

  • Evaluating the construct selection process during the clinical development phase
  • Areas to focus on preclinical studies that will enable better translation to clinical outcome
  • Accelerated mRNA development using our approach
  • clock

    17:40

    Opportunities and Challenges for extrahepatic delivery of therapeutics mRNA

    Daniel Tondera

    Daniel Tondera, Head of Biology, Pantherna Therapeutics GmbH

  • Physicochemical properties of Lipid-nanoparticles impact on their delivery capabilities depending on the administration route
  • Discussion of extrahepatic delivery and therapeutic opportunities in the lung
  • Challenges for preclinical translation associated with LNP delivery capabilities (Example PAN004)
  • clock

    7:00

    Registration & Coffee

    clock

    7:50

    Chairman's Opening Remarks

    clock

    8:00

    Targetted RNA Therapeutics approaches to develop transformational siRNA’s for neurological disorders

  •  Identifying patterns in RNA processing to target for the restoration of physiological function
  • Exploring the development of small molecule therapies as a tool to modulate RNA processing
  • Addressing the underlying drivers of disease through RNA modulation
  • clock

    8:30

    Maximising the treatment potential of RNAis using the PHYOX program for Primary Hyperoxaluria

    Michael T. Migawa

    Michael T. Migawa, Executive Director, Medicinal Chemistry and Oligonucleotide Chemitry, Ionis Pharmaceuticals Inc.

  • GalXC technology platform uses RNAi to inhibit the expression of disease-causing genes by destroying the messenger RNAs of selected genes
  • Establishing PHYOX clinical trials programme
  • Potential to treat diseases by silencing previously inaccessible drug targets
  • clock

    9:00

    Session resereved for sponsor

    clock

    9:30

    Harnessing the power of RNA interference – targeting RNA modifying enzymes for the treatment of NASH

    Stuart Weiss

    Stuart Weiss, Director , Arrowhead Research

  • An introduction to non-alcoholic steatohepatitis and the current treatment challenges associated with the disease
  • Enhancing therapeutic prospects through the development of the ARO-PNPLA3 & GSK4532990 and closer looks at the drugs mechanisms of action
  • Lessons from the current results and a review of next steps in the treatment of non-alcoholic steatohepatitis
  • clock

    10:00

    Morning Coffee

    clock

    10:30

    Session Resereved for Sponsor

    clock

    11:00

    Identifying high value targets for RNAi therapeutics using human

    Paul Nioi

    Paul Nioi, Vice President, Discovery and Translational Research, Alnylam

  • RNAi is a powerful means of accessing previously undruggable targets
  • Identifying suitable targets for RNAi-mediated knockdown can be challenging
  • Human genetics is a very valuable approach for target identification
  • Case study on identifi cation of a new RNAi target for T2D using genetics

     

  • clock

    11:30

    Antibody Oligonucleotide Conjugates for the Treatment of Muscle Disorders

    Ramana Doppalapudi

    Ramana Doppalapudi, Vice President, Chemistry, Avidity Biosciences

  • Challenges with oligonucleotide delivery
  • Development of antibody oligonucleotide conjugates (AOC) for the delivery of oligonucleotides
  • Application of AOC technology for the treatment of rare muscle genetic disorders
  • clock

    12:00

    Phase III: Validation of therapeutic mode of action for heart failure program

    Thomas Thum

    Thomas Thum, Founder and Chief Scientific Officer, Cardior Pharmaceuticals

  • The landscape of microRNA for targeted therapy and miR-132’s key role in cardiovascular diseases
  • Investigating the molecular mechanisms of microRNAs in modulating cardiomyocyte contractility
  • Understanding the study findings and the approach of blocking miR-132 to halt the process of cardiac disease
  • clock

    12:30

    Session Resereved for Sponsor

    clock

    13:00

    Networking Lunch

    clock

    14:00

    Chairs Opening Remarks

    clock

    14:10

    Introducing flexibility in the production of mRNA therapeutics & vaccines to optimise their function

    Toby Murtagh

    Toby Murtagh, Senior Process Validation & Qualification Expert, CureVac

  • Considering the importance of early research decision making for future scale development and regulatory considerations
  • Unlocking end-to-end mRNA drug development for scalable, affordable and commercially viable mRNA production
  • Outlining potential risks to the drug substance resulting from a flexible manufacturing process
  • clock

    14:40

    Session resereved for sponsor

    clock

    15:10

    Considerations for the terminal sterilization of nucleic acid drug products

    Michael  Davies

    Michael Davies, Scientist, MiNa Therapeutics Ltd

  • Effectively selecting a finish-fill methodology that maintains integrity and sterility
  • Successfully introducing a sterile manufacturing process for RNA manufacturing to overcome challenges in technology transfer
  • Exploring current regulatory expectations and provide our interpretation as it pertains to oligonucleotide drug products
  • clock

    15:40

    Afternoon Tea

    clock

    16:10

    Manufacturing therapeutic oligonucleotides - the challenges of scale, cost and sustainability

    David Tew

    David Tew, Senior Scientific Director, GSK

  • Solid phase vs liquid phase methods
  • New chemistries for oligonucleotide synthesis
  • The use of enzymes in oligonucleotide synthesis
  • Thoughts on how these new methods will help to address costand sustainability issues
  • clock

    16:40

    Session Resereved for Sponsor

    clock

    17:10

    Current CMC Regulatory Challenges in RNA Development

    John Bryson

    John Bryson, CMC Lead, Locanabio

  • Overview of key CMC regulatory challenges during the clinical development phase
  • Exploring molecular mechanisms of cytotoxicity to better design future RNA therapeutics
  • Regulatory strategies for use of platform data and prior knowledge
     
  • clock

    17:40

    An Update on the Mission, Goals and Progress of the UK Nucleic Acid Therapy Accelerator

    Nick Lench

    Nick Lench, Executive Director, NATA

  • Introduction to the aims and mission of NATA in supporting the development of RNA Therapeutics and the long-term vision of the organization
  • Insight into the NATA’s current focus on short oligonucleotides and case studies on siRNAs and ASOs
  • The NATA’s funding calls to address challenges in the delivery of RNA Therapeutics
     
  • clock

    14:00

    Chair's Opening Remarks

    clock

    14:10

    Overcoming challenges with immunogenicity for RNA Therapeutics

    Giandomenico Turchiano

    Giandomenico Turchiano, Associate Director, Gene Editing Safety, AstraZeneca

  • Highlighting how the safety of RNA depends on the accuracy of detection
  • Profiling immunogenicity of currently approved RNA therapies
  • Case study from AstraZeneca’s RNA and ASO programmes
  •  Optimising the development of animal models for nucleic acid therapeutics
  • clock

    14:40

    Session resereved for sponsor

    clock

    15:10

    Recent Advances in the Development of Splice Switching Oligonucleotides for CNS Diseases

    Daniel Elbaum

    Daniel Elbaum, CSO, Quralis

  • RNAi is a powerful means of accessing previously undruggable targets
  • Identifying suitable targets for RNAi-mediated knockdown can be challenging
  • Human genetics is a very valuable approach for target identification
  • Case study on identifi cation of a new RNAi target for T2D using genetics
  • clock

    15:40

    Afternoon Tea

    clock

    16:10

    The FORCETM platform overcomes barriers of oligonucleotide delivery to muscle and corrects myotonic dystrophy features in preclinical models

    Stefano Zanotti

    Stefano Zanotti, Executive Director, Head of Neuromuscular Research, Dyne Therapeutics

  • Introduction to the FORCE platform
  • DYNE-101: application of the FORCE platform for the treatment of myotonic dystrophy type I
  • Insight into DYNE-101 delivery in NHP
  • clock

    16:40

    Session resereved for sponsor

    clock

    17:10

    Overcoming challenges with immunogenicity for RNA THerapeutics

  • Highlighting how the safety of RNA depends on the accuracy of detection
  • Profiling immunogenicity of currently approved RNA therapies
  • Case study from AstraZeneca’s RNA and ASO programmes
  • Optimising the development of animal models for nucleic acid therapeutics
  • clock

    17:40

    Improving translational relevancy with cerebral organoids for developing RNA oligonucleotide therapies

    Haiyan Zhou

    Haiyan Zhou, Associate Professor, Group leader, University College London

  • Understanding and overcoming the issues with the use of primary tissue culture
  • Strategic use of organoids to reduce animal use and improve patient safety
  • Outlining the context for the use of organoids in drug development beyond modelling the blood-brain barrier
  • Ensuring the scalability and reproducibility of results with complex in-vitro models

  • Senior Principal Scientist
    Stoke Therapeutics Inc
    Head of Biotherapeutics and Advanced Therapies
    MHRA
    CSO
    Quralis
    Head of Biology
    Pantherna Therapeutics GmbH
    CSO
    Sirnaomics, Inc
    Senior Scientific Director
    GSK
    Senior Director, Discovery Chemistry
    Moderna
    Principal Scientist
    AstraZeneca
    Lab Head Drug Targeting & Vectors
    Bayer AG Pharmaceuticals
    CSO
    Secarna Pharmaceuticalsá
    Associate Director, Gene Editing Safety
    AstraZeneca
    Associate Professor, Group leader
    University College London
    Senior Scientist
    Johannes Gutenberg University Mainz
    Principal Scientist
    AbbVie
    Vice President Research, RNA Therapeutics & Delivery
    Sirnaomics, Inc
    Head of RNA Production and Analytics
    Ethris GmbH
    CMC Lead
    Locanabio
    Director Early-Stage Formulation Process Development
    BioNTech SE
    Director Early-Stage Formulation Process Development
    BioNTech SE
    Research Scientist
    Roche
    Co-Founder & CTO
    Envisagenics
    Scientist
    MiNa Therapeutics Ltd
    Executive Director, Medicinal Chemistry and Oligonucleotide Chemitry
    Ionis Pharmaceuticals Inc.
    Global Head of Patient Safety and Pharmacovigilance
    Biogen International GmbH
    Advisor
    Senior VP
    Alnylam Pharmaceuticals
    Co-Founder and CMO
    MiNA Therapeutics
    Executive Director
    NATA
    Vice President, Discovery and Translational Research
    Alnylam
    CSO
    Capstan Therapeutics
    Vice President, Chemistry
    Avidity Biosciences
    Vice President Oligonucleotide Discovery
    AstraZeneca
    Executive Director, Head of Neuromuscular Research
    Dyne Therapeutics
    Scientist
    ProQR
    Director
    Arrowhead Research
    Vice President, Preclinical Development
    Ionis Pharmaceuticals
    Vice President, Global Head of RNA and Targeted Therapeutics
    Janssen Pharmaceutical Companies of Johnson & Johnson
    Senior Scientist
    GSK
    Founder and Chief Scientific Officer
    Cardior Pharmaceuticals
    Founder and Chief Scientific Officer
    Cardior Pharmaceuticals
    Senior Process Validation & Qualification Expert
    CureVac
    Associate Director
    Evox Therapeutics Ltd

    Sponsors

    Exhibitors

    VENUE

    London Marriott Hotel Grosvenor Square

    Grosvenor Square, London, United Kingdom

    A number of our clients have been approached by third party organisations offering to book hotel rooms. We would advise that you do not book through them as they are not representing the SMi Group. SMi Group books all hotel rooms directly. If you are approached by a third party organisation then please contact us before making any bookings. If you have already booked a hotel room using a third party organisation, we would highly recommend contacting the hotel you were booked into to ensure a booking has been made for you. We would also advise you to please check the terms and conditions of the booking carefully.
    HOTEL BOOKING FORM

    Sponsorship Prospectus

    Download

    Speaker Presentation

    Download

    Speaker Presentation

    Download

    Speaker Presentation

    Download

    Speaker Presentation

    Download

    Speaker Presentation

    Download

    Sponsors


    Micropore

    Sponsors
    https://microporetech.com/

    Micropore is a solution provider in the formulation space to the pharma and biopharma sectors.

    Simply put, Micropore gives clients exquisite control over their chemistry, with consequent shortening of timeframes, improvements in yield and product performance while, in some cases, eliminating process steps.

    Micropore’s technology

    • is formulation agnostic across all nanoparticles formulations.

    • is also solvent agnostic, as all materials of construction are 316L stainless steel, giving complete freedom in formulation.

    • is capable of seamlessly scaling from an initial 200µL sample to full Part 11 compliant GMP manufacturing at 2,000 Litres/hour…….and anything in between.

    • can speed time to market. We have seen a microsphere formulation go from first lab experiment to first engineering batch in 7 months.

    • allows a wide variety of sterilisation methods (CIP, SIP, Pressurised hot water, Autoclave out of place). There are no consumables.

    • is a very gentle process which runs at <5 Bag; typically 1-2 Bar, thereby preserving the integrity of sensitive materials while simultaneously improving our client’s ESG footfrint.

    We work in partnership to help clients all through their formulation journey; from initial scoping and proof of concept through to manufacturing plant design to meet client’s CMC requirements, DQ/IQ/OQ certification and PQ support.

    The company is headquartered in the UK and has subsidiaries in the USA and India together with distributors in Australia and Japan.



    Tebu-bio

    Sponsors
    https://www.tebu-bio.com/

    Our vision of helping to advance Life Sciences research every day, is embodied by providing a unique, holistic range of solutions to make life easier – easily and quickly accessible.

    The full scope of your needs is at the centre of our attention. Our experts provide reliable, multimodal solutions, encompassing our extensive range of products, in-house laboratory platforms, and our practical administrative and logistics services. You’ll find the right combination of answers to accelerate your daily work, in one place.

    Enjoy local access to global solutions, always within easy reach at one of our 9 local offices in Europe


    Exhibitors


    Unchained Labs

    Exhibitors
    https://www.unchainedlabs.com/

    Here’s the deal. We’re all about helping biologics and gene therapy researchers break free from tools that just don’t cut it. Unleashing problem-tackling products that make a huge difference in the real science they do every day. That’s our mantra, our promise and we own it.


    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    London Marriott Hotel Grosvenor Square

    Grosvenor Square
    London W1K 6JP
    United Kingdom

    London Marriott Hotel Grosvenor Square

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out